Diplomat Pharmacy, Inc. (DPLO) to Release Quarterly Earnings on Tuesday
Diplomat Pharmacy, Inc. (NYSE:DPLO) is set to issue its quarterly earnings data after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of $0.15 per share for the quarter. Diplomat Pharmacy has set its FY17 guidance at $0.71-0.79 EPS.
Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Monday, August 7th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.14 billion. During the same quarter in the prior year, the company earned $0.23 EPS. The business’s revenue was up 3.5% compared to the same quarter last year. On average, analysts expect Diplomat Pharmacy to post $0.75 EPS for the current fiscal year and $0.77 EPS for the next fiscal year.
Diplomat Pharmacy, Inc. (DPLO) opened at 21.16 on Tuesday. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 115.63 and a beta of 0.73. The stock has a 50 day moving average price of $20.21 and a 200 day moving average price of $17.33. Diplomat Pharmacy, Inc. has a 12 month low of $12.25 and a 12 month high of $29.17.
COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/24/diplomat-pharmacy-inc-dplo-to-release-quarterly-earnings-on-tuesday.html.
A number of brokerages recently issued reports on DPLO. BidaskClub upgraded Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 5th. Needham & Company LLC reiterated a “buy” rating and issued a $23.75 price target (up previously from $19.75) on shares of Diplomat Pharmacy in a report on Wednesday, October 4th. Zacks Investment Research upgraded Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 price target for the company in a report on Tuesday, October 10th. Robert W. Baird upgraded Diplomat Pharmacy to a “positive” rating and boosted their price target for the company from $20.00 to $24.00 in a report on Monday, September 18th. Finally, TheStreet upgraded Diplomat Pharmacy from a “d+” rating to a “c-” rating in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.69.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.